Search

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

Congratulations to the 2021 Research Grant winners!

The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.

Read more

Young researchers to benefit from EHA training and mentoring

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Read more

Writing and Publications WG

Responsibilities:
Authoring project and consensus papers.

Read more

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.

Read more

Clinical WG

Responsibilities:
Identifying the clinical data required for collection. Locating clinical trials where suitable samples will be collected or have already been collected. Involvement in the European Registry. Assessing the type of database and dataset currently available.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Current status of the Clinical Trials Regulation

HemAffairs Article #2 – June 2019

In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.

Read more